Format

Send to

Choose Destination
BMJ Open. 2019 Dec 18;9(12):e030062. doi: 10.1136/bmjopen-2019-030062.

Opportunities for antibiotic optimisation and outcome improvement in patients with negative blood cultures: study protocol for a cluster-randomised crossover trial, the NO-BACT study.

Author information

1
Clinical Research and Clinical Trials Unit, Hospital Universitario Virgen del Rocío, Seville, Spain silviajimenezjorge@gmail.com.
2
Infectious Diseases and Clinical Microbiology Department, Hospital Universitario Virgen Macarena. Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen Macarena, Seville, Spain.
3
Clinical Research and Clinical Trials Unit, Hospital Universitario Virgen del Rocío, Seville, Spain.
4
Department of Clinical Pharmacology, Virgen del Rocío University Hospital, Seville, Spain.
5
Internal Medicine Department, Hospital Universitario Virgen Macarena, Sevilla, Spain.

Abstract

INTRODUCTION:

Patients with negative blood cultures (BCx) represent 85%-90% of all patients with BCx taken during hospital admission. This population usually includes a heterogeneous group of patients admitted with infectious diseases or febrile syndromes that require a blood culture. There is very little evidence of the clinical characteristics and antibiotic treatment given to these patients.

METHODS AND ANALYSIS:

In a preliminary exploratory prospective cohort study of patients with BCx taken, the clinical/therapeutic characteristics and outcomes/antimicrobial stewardship opportunities of a population of patients with negative BCx will be analysed. In the second phase, using a cluster randomised crossover design, the implementation of an antimicrobial stewardship intervention targeting patients with negative BCx will be evaluated in terms of quality of antimicrobial use (duration and de-escalation), length of hospital stay and mortality.

ETHICS AND DISSEMINATION:

This study has been and registered with clinicaltrials.gov. The findings of our study may support the implementation in clinical practice of an antimicrobial stewardship intervention to optimise the use of antibiotics in patients with negative BCx. The results of this study will be published in peer-reviewed journals and disseminated at national and international conferences.

TRIAL REGISTRATION NUMBER:

NCT03535324.

KEYWORDS:

antibiotic prescribing; antimicrobial stewardship programs; cluster randomised controlled trial; negative blood culture

Conflict of interest statement

Competing interests: ZRP-B reports personal fees from Gilead, outside the submitted work. JR-B and PR participated in accredited educational activities supported by Merck through unrestricted grants, outside the submitted work.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center